Work

MLL-AF9 leukemias are sensitive to PARP1 inhibitors combined with cytotoxic drugs

Year: 2017

Type: article

Abstract: PARP1 is required for the maintenance of MLL-AF9 leukemias.PARP1 inhibitors enhance the therapeutic effect of cytotoxic drugs against MLL-AF9 leukemias.

Source: Blood Advances

DOI: 10.1182/bloodadvances.2017006247

Authors: Silvia Maifrede, Esteban Martinez, Margaret Nieborowska-Skorska, Daniela Di Marcantonio, Michael Hulse, Bac Viet Le, Huaqing Zhao, Katarzyna Piwocka, Italo Tempera, Stephen M. Sykes, Tomasz Skorski

Institutions: Temple University, Fox Chase Cancer Center, Instytut Biologii Doświadczalnej im. Marcelego Nenckiego

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,800

Funder: National Cancer Institute

Awards: Targeting DNA repair to eradicate TKi-refractory/resistant CML and Ph+ALL, Foxo transcription factors are required for maintenance of acute myeloid leukemia, "BCR/ABL-PI-3k-ROS pathway induce genomic instability ...."

OpenAlex ID: W2742501530

FWCI: 1.053

Cites: 28

Cited by: 30

Related to: 10